HomeCompareCCWF vs ABBV

CCWF vs ABBV: Dividend Comparison 2026

CCWF yields 125000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CCWF wins by $4.4870750575756587e+27M in total portfolio value
10 years
CCWF
CCWF
● Live price
125000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.4870750575756587e+27M
Annual income
$4,480,024,748,164,424,300,000,000,000,000,000.00
Full CCWF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CCWF vs ABBV

📍 CCWF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCWFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCWF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCWF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCWF
Annual income on $10K today (after 15% tax)
$10,625,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,808,021,035,939,760,400,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CCWF beats the other by $3,808,021,035,939,760,400,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCWF + ABBV for your $10,000?

CCWF: 50%ABBV: 50%
100% ABBV50/50100% CCWF
Portfolio after 10yr
$2.2435375287878293e+27M
Annual income
$2,240,012,374,082,212,200,000,000,000,000,000.00/yr
Blended yield
99.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CCWF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCWF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCWFABBV
Forward yield125000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.4870750575756587e+27M$102.3K
Annual income after 10y$4,480,024,748,164,424,300,000,000,000,000,000.00$24,771.77
Total dividends collected$4.486613188508161e+27M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CCWF vs ABBV ($10,000, DRIP)

YearCCWF PortfolioCCWF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,510,700$12,500,000.00$11,550$430.00+$12.50MCCWF
2$14,628,690,187$14,615,303,738.32$13,472$627.96+$14628.68MCCWF
3$15,987,233,390,392$15,971,580,691,892.04$15,906$926.08+$15987233.37MCCWF
4$16,330,037,182,147,600$16,312,930,842,419,880.00$19,071$1,382.55+$16330037182.13MCCWF
5$15,590,107,113,307,974,000$15,572,633,973,523,075,000.00$23,302$2,095.81+$15590107113307.95MCCWF
6$13,911,095,050,184,500,000,000$13,894,413,635,573,263,000,000.00$29,150$3,237.93+$13911095050184500.00MCCWF
7$11,601,822,386,032,217,000,000,000$11,586,937,514,328,520,000,000,000.00$37,536$5,121.41+$11601822386032216064.00MCCWF
8$9,043,703,820,318,592,000,000,000,000$9,031,289,870,365,538,000,000,000,000.00$50,079$8,338.38+$9.043703820318592e+21MCCWF
9$6,589,074,216,106,539,000,000,000,000,000$6,579,397,453,018,798,000,000,000,000,000.00$69,753$14,065.80+$6.589074216106539e+24MCCWF
10$4,487,075,057,575,658,400,000,000,000,000,000$4,480,024,748,164,424,300,000,000,000,000,000.00$102,337$24,771.77+$4.4870750575756587e+27MCCWF

CCWF vs ABBV: Complete Analysis 2026

CCWFStock

Church & Crawford, Inc. provides mobile to company integration (MTCI) application to system integrators in the Middle East and Pakistan. It offers Orexis Solution application, a customer contact application platform for mobile phones. The company's application enables users to navigate the graphical user interface to select options for self-service or to interact with the company via instant chat or voice. Church & Crawford, Inc. provides Orexis Solution application under software license agreement with Orexis Technology Research LLC. The company was formerly known as RentFinders USA, Inc. and changed its name to Church & Crawford, Inc. in March 2007. Church & Crawford, Inc. is based in Toronto, Canada.

Full CCWF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CCWF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCWF vs SCHDCCWF vs JEPICCWF vs OCCWF vs KOCCWF vs MAINCCWF vs JNJCCWF vs MRKCCWF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.